Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin augmentation of trauma-focused CBT for PTSD
NL-OMON34768Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing TF-CBT + oxytocin with TF-CBT + placebo (2 arms). Primary endpoints: Change in heart rate during exposure sessions, Change in heart rate variability during exposure sessions and 4 more. Started Apr 2013; status: active, not recruiting.
02
Drugs
oxytocin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NL-OMON34768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34768.